Triamcinolone acetonide was first approved by the U.S. Food and Drug Administration (FDA) for medical use in the United States in 1957.

Triamcinolone acetonide is commonly employed to treat inflammatory and pruritic manifestations of dermatologic disorders, such as eczema, dermatitis, and psoriasis. Furthermore, it is utilized for managing inflammatory joint conditions like arthritis, bursitis, and tendonitis, often administered via intra-articular injection. Additionally, it serves a role in managing respiratory conditions like asthma and allergic rhinitis, with inhalation formulations available for this purpose. In ophthalmology, it is used to treat ocular inflammation and allergic conjunctivitis. Moreover, it finds application in the treatment of oral conditions like aphthous ulcers.

Triamcinolone acetonide is available as a 40mg injection which can be administered intravenously by your doctor. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.

Triamcinolone acetonide use may lead to several side effects, which can vary in severity and occurrence. Common side effects include skin irritation, dryness, thinning, and easy bruising. Additionally, it might cause symptoms such as headache, dizziness, nausea, stomach pain, increased sweating, and mood changes. More serious side effects may include allergic reactions, vision changes, swelling, rapid weight gain, high blood pressure, and muscle weakness. Prolonged use can lead to adrenal suppression, osteoporosis, and increased susceptibility to infections.

Triamcinolone acetonide includes the risk of increased susceptibility to infections, the potential for masking the symptoms of infections, the risk of ocular complications with prolonged use, and the potential for causing or exacerbating psychiatric disturbances. Other warnings include the possibility of inducing adrenal suppression, which can persist even after discontinuation, and the increased risk of developing systemic effects, particularly with the use of high doses or for extended periods.

When using Triamcinolone acetonide, take precautions in the presence of infections, monitor for ocular complications with prolonged use, and be cautious with individuals with a history of psychiatric disorders. Watch for signs of adrenal suppression and minimize the risk of systemic effects by using the lowest effective dose for the shortest duration. Monitor bone health in individuals at risk of osteoporosis and avoid abrupt discontinuation to prevent adrenal insufficiency. Regular consultations with a healthcare provider are crucial for safe and effective medication use.

Be careful if you have any infections, eye problems like glaucoma, or issues with your bones, blood sugar, or mood before taking Triamcinolone acetonide. Watch out for stomach problems, changes in your body's salts, or feeling unwell when you stop the medication. Use caution in kids, older people, and those with heart or blood pressure troubles. Do not get live vaccines while using it. If you are expecting a baby or nursing, talk to your doctor to understand any risks. Follow your doctor's advice closely and inform them of any changes or concerns. If you have been using this medicine for a while, do not stop suddenly, as it might make you feel unwell. Talk to your doctor about slowly reducing the dose. Keep an eye on your body's salt levels, especially if you have problems with your kidneys or heart. If you feel sick or have a fever while using this medicine, talk to your doctor to make sure that because of an infection, your body can not fight off as well.

1. Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Electronic Medicines Compendium (EMC), [Revised on 14 Sep 2023][Accessed on 25th Oct 2023], https://www.medicines.org.uk/emc/product/6748/pil#gref
2. Bristol-Myers Squibb Company, US Food and Drug Administration [Revised on June 2011], [Accessed on 25th Oct 2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014901s038lbl.pdf
3. KD Tripathi, Essentials of medical pharmacology, Hormones and Related Drugs: Corticosteroids, seventh edition, 2013, 282-295.
4. American Regent, US Food and Drug Administration, [ Revised on August 2020] [ Accessed on 29th July],https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212593s000lbl.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.